Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000624418 | SCV000741927 | pathogenic | Inborn genetic diseases | 2016-12-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001207460 | SCV001378815 | pathogenic | not provided | 2022-11-01 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 521373). This variant disrupts the p.Asn121 amino acid residue in FLVCR1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 21070897, 22483575, 28559085). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. Disruption of the initiator codon has been observed in individual(s) with sensory and autonomic neuropathy (PMID: 31408049). It has also been observed to segregate with disease in related individuals. This sequence change affects the initiator methionine of the FLVCR1 mRNA. The next in-frame methionine is located at codon 151. This variant is not present in population databases (gnomAD no frequency). |
OMIM | RCV005049619 | SCV005684948 | pathogenic | Posterior column ataxia-retinitis pigmentosa syndrome | 2025-01-21 | no assertion criteria provided | literature only |